Xenomics Signs Research Agreement with Eastern Virginia Medical School to Conduct Human Trials of Prenatal Tests for Genetic Abnormalities; Proprietary Transrenal-DNA Technology May Result in New Early-Pregnancy, Non-Invasive Prenatal Tests.

NEW YORK -- Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has executed a contract with Eastern Virginia Medical School, a leading healthcare and educational institution, to begin human clinical trials of the Company's proprietary diagnostic DNA technology for the creation of completely safe and non-invasive prenatal tests for a range of genetic abnormalities, such as Down syndrome.

The research agreement between Xenomics and Eastern Virginia Medical School (EVMS) of Norfolk, Va., for a collaborative clinical study that will investigate the ability of Xenomics' Transrenal-DNA (Tr-DNA) to detect a number of fetal genetic problems through analysis of urine samples of pregnant women. The clinical study is subject to review and approval by the institutional review board of EVMS.

Xenomics also recently announced execution of a research agreement with North Shore-Long Island Jewish Health System, one of the nation's largest healthcare institutions, to conduct human clinical trials of its technique to detect Down syndrome in unborn children through analysis of maternal urine samples.

"Starting these human trials is an important next step forward for Xenomics. It demonstrates our strong progress in continued execution of our business plan to develop products based on our Tr-DNA technology platform. These are required studies that we expect will lead to application to the FDA for approval, and ultimately to deliver those products to the marketplace," said Dr. Randy White, CEO of Xenomics. "The urine samples and cooperative research that Eastern Virginia Medical School will conduct is expected to provide important data about the potential to use our Transrenal-DNA platform to create valuable medical tests."

Transrenal-DNA is DNA that has passed through the kidneys and is eliminated in the urine. Xenomics scientists discovered that it is possible to detect genetic material of fetal origin that passes through the mother's kidneys into her urine. The Company is working to develop simple urine analysis tests based on its Tr-DNA technology to detect a range of prenatal genetic abnormalities, including Down syndrome, as well as other questions of genetic makeup. Additionally, Xenomics is developing tests for infectious diseases such as AIDS and tuberculosis.

Xenomics scientists believe the Company's Tr-DNA technology can enable the creation of prenatal tests that are more accurate, more informative and can be conducted much earlier in pregnancy than existing DNA analysis methods, such as amniocentesis. In particular, urine analysis offers none of the risks, discomforts or costs associated with amniocentesis, in which amniotic fluid is extracted through a nine-inch needle inserted into the uterus, to obtain fetal DNA.

Dr. Steven Warsof, Associate Professor and Director of Genetics and Prenatal Diagnosis at the Center for Advanced Fetal Therapy at EVMS, who will serve as principal investigator on the trials, said the several-month-long study will examine the urine of pregnant women to detect the presence of four major chromosomal abnormalities, as well as gender information.

"For a prenatal diagnostician the Xenomics technology is the holy grail of prenatal diagnostics," said Dr. Warsof. "If successful, it could revolutionize all of prenatal diagnostics. Currently, many patients are having invasive testing such as amniocentesis or chorionic villi sampling, that puts their pregnancy at some risk, and that risk could be eliminated with this technology."

Equally important, the Xenomics Tr-DNA tests might be able to be performed as early as only 8 weeks into pregnancy -- much earlier than is possible with amniocentesis, or other tests such as the triple screen which are typically performed 16-22 weeks into pregnancy. "To know the answers to these questions about the chromosomal health of the fetus would bring parents much more peace of mind and reduce their anxiety about the pregnancy," said Dr. Warsof. "Also, it could bring medicine's prenatal diagnosis powers within reach of virtually any women anywhere in the world, since it requires only the collection of a urine sample and delivery to a laboratory.

In contrast, the amniocentesis procedure must be conducted in a medical facility. The first amniocentesis for prenatal diagnosis was conducted in 1972. "A simple urine test for prenatal genetic screening would be the culmination of 40 years of scientific inquiry," added Dr. Warsof. "It's what we have been striving for since prenatal diagnosis has been available."

About Eastern Virginia Medical School

Eastern Virginia Medical School serves the region of southeastern Virginia known as Hampton Roads. One of the most populous regions of Virginia, Hampton Roads' largest cities include Chesapeake, Hampton, Newport News, Norfolk, Portsmouth, Suffolk and Virginia Beach. The main campus of EVMS is located in Norfolk, Virginia. EVMS works in partnership with hospitals, physicians, and clinics throughout the region, providing students and residents with a broad base of clinical experience. For the region as a whole, these educational partnerships spread the benefits of an academic medical center throughout the region, improving the quality of life and the quality of health care for the entire community. For more information, visit http://www.evms.edu.

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal-DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal genetic testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://www.trilogy-capital.com/tcp/xenomics/website.html. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.